NAA Services for Anti-HER2
As a world-leading service provider, Creative Biolabs has accumulated extensive experience from the accomplishment of different NAA (natural autoantibody) projects. With the first-class platform and rich experience in NAA detection, we are very proud to provide you a variety of high-quality anti-HER2 antibody services to promote your project development.
Background of Anti-HER2 Antibodies
Human epidermal growth factor receptor (HER) 2 also known as receptor tyrosine-protein kinase erbB-2, CD340 (cluster of differentiation 340), proto-oncogene Neu, Erbb2 (rodent), or ERBB2 (human), is a protein encoded by the ERBB2 gene in humans. The HER2 proto-oncogene ERBB2 is located in chromosome 17q11-q21. Under physiological conditions, this gene encodes a glycoprotein with molecular weight of 185 kDa (p185). HER2, a ligand orphan receptor of the epidermal growth factor receptor (EGFR) family, is expressed in many human tumors. It amplifies signals from other receptors in its family by forming heterodimers. It is involved in the activation of its downstream signaling cascade, which promotes cell proliferation, metastasis, and angiogenesis in tumors. The important role of HER2 in its signaling network has led to the development of anti-HER2 monoclonal antibodies (MAbs) for cancer therapy.
Fig.1 Human epidermal growth factor receptor (HER) Signaling. (Finigan, et al., 2012)
The Role of Anti-HER2 Antibodies in Lung Cancer
Lung cancer is one of the most common invasive malignant tumors, among which non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers, leading to 80% of lung cancer-related deaths. In NSCLC, identification of carcinogenic-driven mutations leads to definitions of different clinical entities and different therapeutic opportunities, as demonstrated in patients with EGFR mutations or anaplastic lymphoma kinase translocations.
At present, the potential role of HER2 as a therapeutic target has been studied in lung cancer patients. HER2 overexpression was reported in 6% to 30% of lung cancer patients and gene amplification was detected in 2% to 20% of lung cancer patients. The high expression of cyclooxygenase (COX)-2 is related to the progress of NSCLC, which is a rate-limiting enzyme that synthesizes prostaglandins from arachidonic acid. Compared with primary cancer, the expression of COX-2 in lymph node metastasis is significantly increased. Evidence suggests that HER2 increases COX-2 expression by activating MEK (MAPK [mitogen-activated protein kinase]/ERK kinase)/ERK pathway, and then induces cell proliferation and invasion in NSCLC tissues by serine/threonine kinase (AKT) pathway. At present, a large number of studies have confirmed the abnormal regulation of HER2 in non-small cell lung cancer, including overexpression, amplification, and mutation, showing its potential role as a therapeutic biomarker.
What We Can Do about NAA?
NAAs are produced naturally without exogenous Ag stimulation and play important roles in disease detection and non-invasive diagnosis. We are able to offer a full range of NAA services, including NAA detection, NAA profiling, NAA affinity measurement, NAA epitope mapping, and paratope mapping. Sufficient NAA products are available for your choice.
Creative Biolabs is dedicated to providing a variety of NAA services to help you detect lung cancer-associated autoantibodies in a timely and cost-effective manner using various customized immunochemical assays. Our high-quality products and services will make a significant contribution to the success of your project. Please feel free to contact us for more information and detailed quotations.
Reference:
- Finigan, J. H.; et al. Human epidermal growth factor receptor signaling in acute lung injury. American journal of respiratory cell and molecular biology. 2012, 47(4): 395-404.
Related Services:
- NAA Services for Anti-p53
- NAA Services for Anti-CAGE
- NAA Services for Anti-MUC1 Antibody
- NAA Services for Anti-c-Myc Antibodies
- NAA Services for Anti-GBU4-5